Introduction
Behc ßet's disease (BD) is a systemic vasculitis with mucocutaneous, gastrointestinal, ocular, vascular, and neurological involvement. 1 Ocular manifestations represent one of major organ involvement, with a high rate of recurrences potentially resulting in partial or total blindness. Treatments may range from the topical approach to disease-modifying antirheumatic drugs and biological agents. 1 Tumor necrosis factor (TNF)-a inhibitors and interferon-a are usually effective in the majority of patients with severe ocular disease. 1 Recent clinical observations with the interleukin (IL)-1 inhibiting agents anakinra, 2 canakinumab, [3] [4] [5] and gevokizumab 6 have suggested their potential role in the treatment of refractory Behc ßet's uveitis. Accordingly, in a multicenter retrospective study, we found that treatment with anakinra and canakinumab was effective and safe in 30 patients with BD, with an overall acceptable retention on treatment.
7
Unlike anti-TNFa treatment, IL-1 inhibition has shown a good safety profile regarding the risk of severe infections, particularly in relation to tuberculosis (TB) reactivation. 8 Indeed, interfering with the IL-1 pathway seems safer in comparison with blocking TNFa. This consideration is relevant for patients with BD because of the high prevalence of this disease in geographical areas where TB is a social concern. 8 In this regard, we report herein a patient with BD with concomitant latent TB infection successfully treated with anakinra as first-line biological therapy.
A 41-year-old man was diagnosed with BD in 2008 based on recurrent oral aphthosis, genital ulcerations, and pseudofolliculitis. His medical history was also relevant for monthly fever attacks, spontaneously resolved 1 year after the onset of symptoms, hip arthralgia, and The Quantiferon test was positive. Treatment with corticosteroids (6-methylprednisolone 500 mg/d intravenously for 3 consecutive days followed by shortly tapering oral prednisone until 5 mg/d) and anakinra (100 mg/d subcutaneously) was started. Of note, no other disease-modifying antirheumatic drugs were used before starting anakinra. Despite the use of high-dose corticosteroids and anakinra, anti-TB prophylaxis was not administered because of proven multiple intolerance to anti-TB drugs; in particular, isoniazid and rifampicin were early interrupted due to gastrointestinal (nausea and vomit) and cutaneous (generalized urticaria) manifestations. A good clinical response was rapidly achieved, and the ophthalmologic evaluation performed 7 days after starting the treatment showed a dramatic visual improvement and a marked reduction of the optic nerve head swelling. Further ophthalmological evaluations performed every 2 months highlighted resolution of papillitis, increase of BCVA to 20/25, and absence of ocular inflammation during the following 12 months (Fig. 1) . Anakinra treatment was well tolerated, and no adverse events or signs of TB reactivation occurred. Anti-IL-1 agents are emerging as an important therapeutic option in BD, [2] [3] [4] [5] [6] [7] with a good safety profile. 9 IL-1 is a proinflammatory cytokine secreted by a wide number of cell types, and increased levels of IL-1 play a major role in several disorders including autoinflammatory diseases. 10, 11 In this regard, BD shows several clinical findings overlapping with those of autoinflammatory diseases; 12 moreover, polymorphisms in the IL-1-related genes have proven to confer susceptibility to BD. 13 Interestingly, recent data have shown that IL-1b from peptidoglycan/lipopolysaccharide-induced monocytes is significantly increased in patients with BD with active uveitis, thus providing a pathophysiological rationale for anti-IL-1 treatment in Behc ßet's uveitis.
14 Noteworthy, our patient presented a positive Quantiferon-TB test, thus deserving some attention when starting anti-TNFa treatment. In fact, the risk of TB reactivation when using anti-TNFa agents represents a hot issue particularly in those areas where the infection is endemic, such as along the ancient Silk Road, where BD has a high prevalence and TB is a socioeconomic burden. Conversely, IL-1 inhibitors have shown a better safety profile than anti-TNFa regarding the risk of TB reactivation. 8 Our report suggests that anakinra should not be reserved only to refractory patients with BD but highlights that in selected BD cases it should be taken into consideration also as a first-line biologic drug. This might be relevant particularly when a rapid and persistent therapeutic response is needed, but at the same time, contraindications to anti-TNFa treatment, such as the concomitant TB infection in our patient, are present. 
